Primary splenic angiosarcoma is a very rare,aggressive neoplasm with a high metastatic rate and dismal prognosis. This neoplasm usually presents with abdominal pain, splenomegaly, anemia, and thrombocytopenia. Splenic...Primary splenic angiosarcoma is a very rare,aggressive neoplasm with a high metastatic rate and dismal prognosis. This neoplasm usually presents with abdominal pain, splenomegaly, anemia, and thrombocytopenia. Splenic angiosarcoma with bleeding gastrointestinal metastases is extremely rare. The literature contains only two case reports. This study reported a 44-year-old male patient with splenic angiosarcoma with sustained repeated gastrointestinal bleeding due to small bowel metastases. Salvage surgery was performed by splenectomy and resection of the metastatic small bowel tumors. The post-operative course was uneventful; the patient survived with the disease and had no GI bleeding, 7 mo after surgery.展开更多
目的探讨腹腔镜保脾胰体尾切除术治疗胰体尾肿瘤的安全性和有效性。方法回顾性分析宁波市鄞州人民医院肝胆外科于2012年1月至2017年12月行腹腔镜胰体尾切除术的39例患者的临床资料,按照手术方式分为腹腔镜保脾组(n=11)和腹腔镜切脾组(n=...目的探讨腹腔镜保脾胰体尾切除术治疗胰体尾肿瘤的安全性和有效性。方法回顾性分析宁波市鄞州人民医院肝胆外科于2012年1月至2017年12月行腹腔镜胰体尾切除术的39例患者的临床资料,按照手术方式分为腹腔镜保脾组(n=11)和腹腔镜切脾组(n=28)。经倾向性得分配对后,两组各10例纳入研究,比较两组术中情况及术后近远期并发症情况等。结果保脾组与脾切除组手术时间[(175.3±47.6)min vs (187.6±56.7)min,P=0.15]、切除病灶直径[(31.6±3.7)mm vs (35.8±5.7)mm,P=0.069]差异无统计学意义,但保脾组术中出血量少于切脾组[(45.5±13.4)mL vs (105.9±34.7)mL,P<0.001]。两组术后近期并发症的发生率(80% vs 100%,P=0.531)、胰漏发生率(40% vs 50%,P=0.650)无统计学差异。保脾组术后白细胞(WBC)峰值[(10.6±4.7)×10^9/L vs (15.3±5.9)×10^9/L,P<0.001]以及术后近期血小板(PLT)峰值[(534.0±149.4)×10^12/L vs (718.0±200.9)×10^12/L,P<0.001]低于切脾组,生活质量(QOL)评分[(39.3±8.3) vs (27.0±9.5),P<0.001]优于切脾组。无一例发生爆发性感染。结论腹腔镜保脾胰体尾切除术和腹腔镜切脾胰体尾切除术具有相同的安全性和可行性,腹腔镜保脾胰体尾切除术后患者生活质量更高,血液稳定性更佳。展开更多
文摘Primary splenic angiosarcoma is a very rare,aggressive neoplasm with a high metastatic rate and dismal prognosis. This neoplasm usually presents with abdominal pain, splenomegaly, anemia, and thrombocytopenia. Splenic angiosarcoma with bleeding gastrointestinal metastases is extremely rare. The literature contains only two case reports. This study reported a 44-year-old male patient with splenic angiosarcoma with sustained repeated gastrointestinal bleeding due to small bowel metastases. Salvage surgery was performed by splenectomy and resection of the metastatic small bowel tumors. The post-operative course was uneventful; the patient survived with the disease and had no GI bleeding, 7 mo after surgery.
文摘目的探讨腹腔镜保脾胰体尾切除术治疗胰体尾肿瘤的安全性和有效性。方法回顾性分析宁波市鄞州人民医院肝胆外科于2012年1月至2017年12月行腹腔镜胰体尾切除术的39例患者的临床资料,按照手术方式分为腹腔镜保脾组(n=11)和腹腔镜切脾组(n=28)。经倾向性得分配对后,两组各10例纳入研究,比较两组术中情况及术后近远期并发症情况等。结果保脾组与脾切除组手术时间[(175.3±47.6)min vs (187.6±56.7)min,P=0.15]、切除病灶直径[(31.6±3.7)mm vs (35.8±5.7)mm,P=0.069]差异无统计学意义,但保脾组术中出血量少于切脾组[(45.5±13.4)mL vs (105.9±34.7)mL,P<0.001]。两组术后近期并发症的发生率(80% vs 100%,P=0.531)、胰漏发生率(40% vs 50%,P=0.650)无统计学差异。保脾组术后白细胞(WBC)峰值[(10.6±4.7)×10^9/L vs (15.3±5.9)×10^9/L,P<0.001]以及术后近期血小板(PLT)峰值[(534.0±149.4)×10^12/L vs (718.0±200.9)×10^12/L,P<0.001]低于切脾组,生活质量(QOL)评分[(39.3±8.3) vs (27.0±9.5),P<0.001]优于切脾组。无一例发生爆发性感染。结论腹腔镜保脾胰体尾切除术和腹腔镜切脾胰体尾切除术具有相同的安全性和可行性,腹腔镜保脾胰体尾切除术后患者生活质量更高,血液稳定性更佳。
